UroGen Pharma (URGN) PT Lowered to $25 at Goldman Sachs, After Trial Fails Endpoints
Tweet Send to a Friend
Goldman Sachs analyst Paul Choi ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
